Plasma cell leukemia

An evaluation of response to therapy

Pierre Noel, Robert A. Kyle

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Forty-three patients with plasma cell leukemia were seen at the Mayo Clinic. Twenty-five (58 percent) had primary plasma cell leukemia (diagnosis first made in the leukemic phase) and 18 (42 percent) had secondary plasma cell leukemia (leukemic transformation of a previously diagnosed multiple myeloma). Patients with secondary plasma cell leukemia were older, had a greater incidence of lytic bone lesions, had a lower platelet count, and had a larger M-protein in the serum than did patients with primary plasma cell leukemia. The median survival was 6.8 months for patients with primary plasma cell leukemia and 1.3 months for patients with secondary plasma cell leukemia. In patients with primary plasma cell leukemia, multiple alkylating agents produced a higher response rate than did melphalan, but the median time from treatment to progression or death was not significantly improved with such therapy. Review of the literature also suggests that the response rate is higher with combination chemotherapy than with single alkylating agents. Patients with secondary plasma cell leukemia usually show resistance to any type of chemotherapy and have a short survival.

Original languageEnglish (US)
Pages (from-to)1062-1068
Number of pages7
JournalThe American journal of medicine
Volume83
Issue number6
DOIs
StatePublished - 1987

Fingerprint

Plasma Cell Leukemia
Therapeutics
Alkylating Agents
Melphalan
Survival
Combination Drug Therapy
Multiple Myeloma
Platelet Count
Blood Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Plasma cell leukemia : An evaluation of response to therapy. / Noel, Pierre; Kyle, Robert A.

In: The American journal of medicine, Vol. 83, No. 6, 1987, p. 1062-1068.

Research output: Contribution to journalArticle

Noel, Pierre ; Kyle, Robert A. / Plasma cell leukemia : An evaluation of response to therapy. In: The American journal of medicine. 1987 ; Vol. 83, No. 6. pp. 1062-1068.
@article{756ac48d0c2544ad94479e70f100c6f3,
title = "Plasma cell leukemia: An evaluation of response to therapy",
abstract = "Forty-three patients with plasma cell leukemia were seen at the Mayo Clinic. Twenty-five (58 percent) had primary plasma cell leukemia (diagnosis first made in the leukemic phase) and 18 (42 percent) had secondary plasma cell leukemia (leukemic transformation of a previously diagnosed multiple myeloma). Patients with secondary plasma cell leukemia were older, had a greater incidence of lytic bone lesions, had a lower platelet count, and had a larger M-protein in the serum than did patients with primary plasma cell leukemia. The median survival was 6.8 months for patients with primary plasma cell leukemia and 1.3 months for patients with secondary plasma cell leukemia. In patients with primary plasma cell leukemia, multiple alkylating agents produced a higher response rate than did melphalan, but the median time from treatment to progression or death was not significantly improved with such therapy. Review of the literature also suggests that the response rate is higher with combination chemotherapy than with single alkylating agents. Patients with secondary plasma cell leukemia usually show resistance to any type of chemotherapy and have a short survival.",
author = "Pierre Noel and Kyle, {Robert A.}",
year = "1987",
doi = "10.1016/0002-9343(87)90942-9",
language = "English (US)",
volume = "83",
pages = "1062--1068",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Plasma cell leukemia

T2 - An evaluation of response to therapy

AU - Noel, Pierre

AU - Kyle, Robert A.

PY - 1987

Y1 - 1987

N2 - Forty-three patients with plasma cell leukemia were seen at the Mayo Clinic. Twenty-five (58 percent) had primary plasma cell leukemia (diagnosis first made in the leukemic phase) and 18 (42 percent) had secondary plasma cell leukemia (leukemic transformation of a previously diagnosed multiple myeloma). Patients with secondary plasma cell leukemia were older, had a greater incidence of lytic bone lesions, had a lower platelet count, and had a larger M-protein in the serum than did patients with primary plasma cell leukemia. The median survival was 6.8 months for patients with primary plasma cell leukemia and 1.3 months for patients with secondary plasma cell leukemia. In patients with primary plasma cell leukemia, multiple alkylating agents produced a higher response rate than did melphalan, but the median time from treatment to progression or death was not significantly improved with such therapy. Review of the literature also suggests that the response rate is higher with combination chemotherapy than with single alkylating agents. Patients with secondary plasma cell leukemia usually show resistance to any type of chemotherapy and have a short survival.

AB - Forty-three patients with plasma cell leukemia were seen at the Mayo Clinic. Twenty-five (58 percent) had primary plasma cell leukemia (diagnosis first made in the leukemic phase) and 18 (42 percent) had secondary plasma cell leukemia (leukemic transformation of a previously diagnosed multiple myeloma). Patients with secondary plasma cell leukemia were older, had a greater incidence of lytic bone lesions, had a lower platelet count, and had a larger M-protein in the serum than did patients with primary plasma cell leukemia. The median survival was 6.8 months for patients with primary plasma cell leukemia and 1.3 months for patients with secondary plasma cell leukemia. In patients with primary plasma cell leukemia, multiple alkylating agents produced a higher response rate than did melphalan, but the median time from treatment to progression or death was not significantly improved with such therapy. Review of the literature also suggests that the response rate is higher with combination chemotherapy than with single alkylating agents. Patients with secondary plasma cell leukemia usually show resistance to any type of chemotherapy and have a short survival.

UR - http://www.scopus.com/inward/record.url?scp=0023634218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023634218&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(87)90942-9

DO - 10.1016/0002-9343(87)90942-9

M3 - Article

VL - 83

SP - 1062

EP - 1068

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -